Search Results

Dr. Ahmad Cheema is a fellowship-trained, board-certified medical oncologist and hematologist. He earned his medical degree from the Services Institute of Medical Sciences in Pakistan, followed by Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai/St. Luke’s-Roosevelt Hospital Center. He then completed his Hematology and Oncology fellowship at West Virginia University.…

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations Brief Summary: The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid…

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies Brief Summary: The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.…

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Brief Summary: The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and…

Jennifer Vaz, MD received her medical degree from the Medical College of Virginia before completing a residency in gynecology and obstetrics at Inova Fairfax Hospital. She completed a gynecologic oncology fellowship at the Medical College of Georgia. Following her medical training, Dr. Vaz served as both a gynecologic oncologist and assistant professor of obstetrics and…

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment – DS1062-328 MOA: Dato-DXD is an ADC that comprises a recombinant humanized anti-TROP2 IgG1…